News

The weight-loss drug boom has dominated headlines for the last two years — but underneath the hype lies a major flaw in the ...
Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...
Reduced monthly costs for uninsured patients still amount to around $500. That can put the drugs out of reach for many.
Insurers are cutting coverage, citing costs. But there’s seldom any discussion of the return on investment from these drugs ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
CVS Caremark has removed coverage of Zepbound, a GLP-1 weight-loss drug, citing pricing concerns and shifting payer dynamics ...
Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...
Weight-loss supplements recommended by influencers on social mead are generally ineffective for weight loss, but do have some benefits.
I hear a lot of talk around our small town when someone becomes noticeably thinner. “He sure has lost a lot of weight.” “Did ...
UBS remains bullish on Eli Lilly’s future thanks to surging demand for its obesity and diabetes treatments. UBS predicts ...
They burst onto the scene four years ago and are taking over the pharmaceutical world. New GLP-1-based drugs like Ozempic, Wegovy or Zepbound are said to be a weight-loss game changer and could drive ...
The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.